Qualifying shareholders will be entitled to receive 1 Haleon share for each GSK share held at the record time.
Qualifying shareholders will be entitled to receive 1 Haleon share for each GSK share held at the record time.
The demerger would create two great companies, allowing GSK to lean into biopharma while launching Haleon as an independent global leader in consumer health with the freedom to accelerate its time to market and product innovations.
As a result, each GSK shareholder will have fewer shares, but each remaining share should be more valuable. Consolidation itself does not change the value of someone's GSK shareholding. The consolidation applies only to GSK shares, not the Haleon shares each GSK shareholder received at Demerger.
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Sir Dave Lewis is chairman, with Brian McNamara as CEO. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange.
Also known as a reverse stock split. A reduction in the number of issued and outstanding shares that increases a shareholder's per-share value proportionately.
It should be noted that even if the Exchange's Shareholder approval requirement for a security consolidation is not applicable to a particular security consolidation, the Issuer may still be required to obtain Shareholder approval for the consolidation under applicable corporate laws.
Consolidation of shares is a corporate action where a company reduces the number of outstanding shares by combining the shares and increasing the face value. This is also known as a reverse stock split. The company notifies the shareholders through email before the stock consolidation.